Is there a role for pembrolizumab beyond progression in urothelial carcinoma?

被引：0
|
作者：
Taguchi, Satoru [1 ]
Kawai, Taketo [2 ]
Nakagawa, Tohru [2 ]
Kume, Haruki [1 ]
机构：
[1] Univ Tokyo, Grad Sch Med, Dept Urol, 7-3-1 Hongo,Bunkyo Ku, Tokyo 1138655, Japan
[2] Teikyo Univ, Sch Med, Dept Urol, Tokyo, Japan
来源：
BJU INTERNATIONAL | 2024年 / 134卷 / 01期
关键词：
D O I：
10.1111/bju.16245
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：43 / 44
页数：2
相关论文
共 50 条
  • [1] Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma
    Fukuokaya, Wataru
    Kimura, Takahiro
    Yanagisawa, Takafumi
    Kimura, Shoji
    Tsuzuki, Shunsuke
    Koike, Yuhei
    Iwamoto, Yuya
    Enei, Yuki
    Tanaka, Masatoshi
    Urabe, Fumihiko
    Onuma, Hajime
    Honda, Mariko
    Miki, Jun
    Oyama, Yu
    Abe, Hirokazu
    Egawa, Shin
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (01) : 229 - 236
  • [2] Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma
    Wataru Fukuokaya
    Takahiro Kimura
    Takafumi Yanagisawa
    Shoji Kimura
    Shunsuke Tsuzuki
    Yuhei Koike
    Yuya Iwamoto
    Yuki Enei
    Masatoshi Tanaka
    Fumihiko Urabe
    Hajime Onuma
    Mariko Honda
    Jun Miki
    Yu Oyama
    Hirokazu Abe
    Shin Egawa
    Cancer Immunology, Immunotherapy, 2022, 71 : 229 - 236
  • [3] Pembrolizumab for Advanced Urothelial Carcinoma
    Liang, Fei
    Zhu, Ji
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (23): : 2302 - 2302
  • [4] Pembrolizumab for Advanced Urothelial Carcinoma Reply
    Bellmunt, Joaquim
    Bajorin, Dean F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (23): : 2304 - 2304
  • [5] Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study
    Ito, Katsuhiro
    Kita, Yuki
    Yokomizo, Akira
    Miki, Jun
    Yoshio, Yuko
    Matsumoto, Hiroaki
    Segawa, Takehiko
    Karashima, Takashi
    Nishiyama, Naotaka
    Imai, Kazuto
    Suekane, Shigetaka
    Nagasawa, Seiji
    Higashi, Shin
    Nishiyama, Hiroyuki
    Kitamura, Hiroshi
    Kobayashi, Takashi
    CANCER MEDICINE, 2023, 12 (03): : 2325 - 2332
  • [6] Squamous differentiation is a potential biomarker predicting tumor progression in patients treated with pembrolizumab for urothelial carcinoma
    Miyama, Yu
    Morikawa, Teppei
    Miyakawa, Jimpei
    Koyama, Yuichi
    Kawai, Taketo
    Kume, Haruki
    Ushiku, Tetsuo
    PATHOLOGY RESEARCH AND PRACTICE, 2021, 219
  • [7] Chemoimmunotherapy after progression on single-agent pembrolizumab for metastatic urothelial carcinoma: a case series
    Childs, Daniel S.
    Quevedo, J. Fernando
    Costello, Brian A.
    Pagliaro, Lance C.
    ANTI-CANCER DRUGS, 2021, 32 (09) : 986 - 990
  • [8] Effectiveness of pembrolizumab in patients with urothelial carcinoma inhibitors
    Fukuokaya, Wataru
    Kimura, Takahiro
    Komura, Kazumasa
    Uchimoto, Taizo
    Nishimura, Kazuki
    Yanagisawa, Takafumi
    Imai, Yu
    Iwatani, Kosuke
    Ito, Kagenori
    Urabe, Fumihiko
    Tsuzuki, Shunsuke
    Kimura, Shoji
    Terada, Naoki
    Mukai, Shoichiro
    Oyama, Yu
    Abe, Hirokazu
    Kamoto, Toshiyuki
    Azuma, Haruhito
    Miki, Jun
    Egawa, Shin
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (07) : 346.e1 - 346.e8
  • [9] Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
    Nishimura, Nobutaka
    Miyake, Makito
    Shimizu, Takuto
    Tachibana, Akira
    Tanaka, Nobumichi
    Fujimoto, Kiyohide
    IJU CASE REPORTS, 2022, 5 (05) : 338 - 341
  • [10] Role of Oxidative Stress and Autophagy in Progression of Urothelial Carcinoma of Bladder
    Ojha, R.
    Singh, S.
    Bhattacharyya, S.
    Rakha, A.
    Singh, R.
    Mandal, A.
    Jha, V
    UROLOGY, 2012, 80 (03) : S199 - S200
12345